Kura Oncology and Kyowa Kirin Forge Global Partnership to Develop and Commercialize Ziftomenib for Acute Myeloid Leukemia

Metropolis Healthcare's Landmark Study Highlights the Role of Molecular Profiling in Advancing Lung Cancer Care

Novartis Acquires Kate Therapeutics for $1.1 Billion to Advance Gene Therapies for Neuromuscular Diseases

OneCell Diagnostics Secures $16M to Revolutionize Cancer Diagnostics

FDA Grants Accelerated Approval to Ziihera® (zanidatamab-hrii) for HER2-Positive Biliary Tract Cancer

Illumina Unveils TruSight™ Oncology 500 v2 for Comprehensive Genomic Profiling

Tagomics Partners with Agilent Technologies to Revolutionize Multiomic Biomarker Discovery

Bio-Techne Partners with Leader Life Sciences to Expand in the GCC Region

Owkin and Proscia Partner to Revolutionize MSI Testing for Colorectal Cancer with AI-Powered Solutions

Telix Expands Theranostic Pipeline with FAP-Targeting Radiopharmaceuticals

Alamar Biosciences and The Michael J. Fox Foundation Partner to Advance Parkinson’s Disease Biomarker Discovery

Stilla Technologies Partners with Source BioScience to Advance Genomics in the UK and Ireland

Quell Therapeutics and AstraZeneca Advance CAR-Treg Therapy for Type 1 Diabetes

AbbVie’s ELAHERE® Approved in the EU for Platinum-Resistant Ovarian Cancer

AstraZeneca’s Tagrisso Recommended for Approval in EU for Unresectable EGFR-Mutated NSCLC

Home
/
update
/
details

Novartis Acquires Kate Therapeutics for $1.1 Billion to Advance Gene Therapies for Neuromuscular Diseases

NextEdge Admin

23 Nov 2024

2 min 9 sec

Kate Therapeutics,gene therapies,Neuroscience,Research

Novartis has announced the acquisition of San Diego-based Kate Therapeutics in a deal valued at $1.1 billion, bolstering its portfolio of gene therapies for inherited neuromuscular diseases. The agreement includes an upfront cash payment and additional milestone-based payments.

Kate Therapeutics, a preclinical-stage biotech firm, specializes in adeno-associated virus (AAV)-based gene therapies. The acquisition adds its preclinical candidates targeting Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and myotonic dystrophy type 1 to Novartis' pipeline.

Novartis Neuroscience Research global head Robert Baloh highlighted the strategic importance of the acquisition, stating it enhances Novartis' neuroscience drug discovery capabilities and reinforces its commitment to addressing unmet needs in inherited neuromuscular conditions. He emphasized the acquisition’s role in overcoming the limitations of existing gene therapies.

Kate Therapeutics brings its DELIVER platform, which combines diverse capsid libraries, in vivo selection, and machine learning to evolve capsid variants. This approach enables targeted payload delivery to specific tissues, potentially minimizing off-target effects on organs like the liver.

Fiona Marshall, Novartis Biomedical Research president, praised Kate’s scientific rigor and platform technologies, expressing confidence that this acquisition would strengthen Novartis’ efforts in gene therapy and neuroscience innovation.

The deal follows Novartis’ recent collaboration with Ratio Therapeutics to develop a radiotherapeutic targeting somatostatin receptor 2 for cancer treatment, further underscoring the company’s commitment to advancing cutting-edge therapies.